CALLA: Durvalumab versus placebo with chemoradiotherapy Last updated on Apr 21, 2024 Previous SCORPION: Primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer Next KEYNOTE A18: Pembrolizumab Plus Chemoradiotherapy for High-Risk Locally Advanced Cervical Cancer
